Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Non-Current Deffered Revenue (2016 - 2025)

Historic Non-Current Deffered Revenue for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to $573000.0.

  • Kyntra Bio's Non-Current Deffered Revenue fell 9954.6% to $573000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $573000.0, marking a year-over-year decrease of 9954.6%. This contributed to the annual value of $114.7 million for FY2024, which is 2719.49% down from last year.
  • Kyntra Bio's Non-Current Deffered Revenue amounted to $573000.0 in Q3 2025, which was down 9954.6% from $122.2 million recorded in Q2 2025.
  • Over the past 5 years, Kyntra Bio's Non-Current Deffered Revenue peaked at $205.4 million during Q2 2022, and registered a low of $573000.0 during Q3 2025.
  • For the 5-year period, Kyntra Bio's Non-Current Deffered Revenue averaged around $148.8 million, with its median value being $154.2 million (2023).
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first skyrocketed by 3489.97% in 2021, then plummeted by 9954.6% in 2025.
  • Over the past 5 years, Kyntra Bio's Non-Current Deffered Revenue (Quarter) stood at $186.8 million in 2021, then dropped by 0.58% to $185.7 million in 2022, then fell by 15.17% to $157.6 million in 2023, then fell by 27.19% to $114.7 million in 2024, then crashed by 99.5% to $573000.0 in 2025.
  • Its Non-Current Deffered Revenue was $573000.0 in Q3 2025, compared to $122.2 million in Q2 2025 and $115.3 million in Q1 2025.